Selected research
Industry Research
Olaparib API Industry Research Report 2026
Market perspective
The global Olaparib API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Olaparib API is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Olaparib API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Olaparib API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Olaparib API include Novartis AG, Pfizer, Bayer AG, Transo-Pharm USA LLC, Sun Pharmaceutical Industrial, ScinoPham Taiwan, MSN Laboratories, Exelixis and DR. Reddy's Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Olaparib API market in terms of revenue (US$ million) and, where applicable, sales volume (Kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Olaparib API Market by Company
Novartis AG
Pfizer
Bayer AG
Transo-Pharm USA LLC
Sun Pharmaceutical Industrial
ScinoPham Taiwan
MSN Laboratories
Exelixis
DR. Reddy's Laboratories
AstraZeneca
ALP Pharm Beijing
Alembic Pharmaceuticals
Olaparib API Segment by Type
Ovarian Cancer
Prostate Cancer
Breast Cancer
Pancreatic Cancer
Olaparib API Segment by Application
Pharmaceuticals
Biomedical
Others
Olaparib API Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Olaparib API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Olaparib API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Olaparib API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Olaparib API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Olaparib API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Olaparib API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ovarian Cancer
- Prostate Cancer
- Breast Cancer
- Pancreatic Cancer
Applications
- Pharmaceuticals
- Biomedical
- Others
Companies covered
- Novartis AG
- Pfizer
- Bayer AG
- Transo-Pharm USA LLC
- Sun Pharmaceutical Industrial
- ScinoPham Taiwan
- MSN Laboratories
- Exelixis
- DR. Reddy's Laboratories
- AstraZeneca
- ALP Pharm Beijing
- Alembic Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Olaparib API Market Size (2021-2032)
- 2.2.2 Global Olaparib API Sales (2021-2032)
- 2.2.3 Global Olaparib API Market Average Price (2021-2032)
- 2.3 Olaparib API by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ovarian Cancer
- 2.3.3 Prostate Cancer
- 2.3.4 Breast Cancer
- 2.3.5 Pancreatic Cancer
- 2.4 Olaparib API by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Pharmaceuticals
- 2.4.3 Biomedical
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Olaparib API Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Olaparib API Sales (Kg) of Manufacturers (2021-2026)
- 3.3 Global Olaparib API Revenue of Manufacturers (2021-2026)
- 3.4 Global Olaparib API Average Price by Manufacturers (2021-2026)
- 3.5 Global Olaparib API Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Olaparib API, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Olaparib API, Product Type & Application
- 3.8 Global Manufacturers of Olaparib API, Established Date
- 3.9 Global Olaparib API Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Olaparib API Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Olaparib API Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 Pfizer
- 4.2.1 Pfizer Company Information
- 4.2.2 Pfizer Business Overview
- 4.2.3 Pfizer Olaparib API Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pfizer Olaparib API Product Portfolio
- 4.2.5 Pfizer Recent Developments
- 4.3 Bayer AG
- 4.3.1 Bayer AG Company Information
- 4.3.2 Bayer AG Business Overview
- 4.3.3 Bayer AG Olaparib API Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bayer AG Olaparib API Product Portfolio
- 4.3.5 Bayer AG Recent Developments
- 4.4 Transo-Pharm USA LLC
- 4.4.1 Transo-Pharm USA LLC Company Information
- 4.4.2 Transo-Pharm USA LLC Business Overview
- 4.4.3 Transo-Pharm USA LLC Olaparib API Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Transo-Pharm USA LLC Olaparib API Product Portfolio
- 4.4.5 Transo-Pharm USA LLC Recent Developments
- 4.5 Sun Pharmaceutical Industrial
- 4.5.1 Sun Pharmaceutical Industrial Company Information
- 4.5.2 Sun Pharmaceutical Industrial Business Overview
- 4.5.3 Sun Pharmaceutical Industrial Olaparib API Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sun Pharmaceutical Industrial Olaparib API Product Portfolio
- 4.5.5 Sun Pharmaceutical Industrial Recent Developments
- 4.6 ScinoPham Taiwan
- 4.6.1 ScinoPham Taiwan Company Information
- 4.6.2 ScinoPham Taiwan Business Overview
- 4.6.3 ScinoPham Taiwan Olaparib API Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 ScinoPham Taiwan Olaparib API Product Portfolio
- 4.6.5 ScinoPham Taiwan Recent Developments
- 4.7 MSN Laboratories
- 4.7.1 MSN Laboratories Company Information
- 4.7.2 MSN Laboratories Business Overview
- 4.7.3 MSN Laboratories Olaparib API Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 MSN Laboratories Olaparib API Product Portfolio
- 4.7.5 MSN Laboratories Recent Developments
- 4.8 Exelixis
- 4.8.1 Exelixis Company Information
- 4.8.2 Exelixis Business Overview
- 4.8.3 Exelixis Olaparib API Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Exelixis Olaparib API Product Portfolio
- 4.8.5 Exelixis Recent Developments
- 4.9 DR. Reddy's Laboratories
- 4.9.1 DR. Reddy's Laboratories Company Information
- 4.9.2 DR. Reddy's Laboratories Business Overview
- 4.9.3 DR. Reddy's Laboratories Olaparib API Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 DR. Reddy's Laboratories Olaparib API Product Portfolio
- 4.9.5 DR. Reddy's Laboratories Recent Developments
- 4.10 AstraZeneca
- 4.10.1 AstraZeneca Company Information
- 4.10.2 AstraZeneca Business Overview
- 4.10.3 AstraZeneca Olaparib API Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AstraZeneca Olaparib API Product Portfolio
- 4.10.5 AstraZeneca Recent Developments
- 4.11 ALP Pharm Beijing
- 4.11.1 ALP Pharm Beijing Company Information
- 4.11.2 ALP Pharm Beijing Business Overview
- 4.11.3 ALP Pharm Beijing Olaparib API Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 ALP Pharm Beijing Olaparib API Product Portfolio
- 4.11.5 ALP Pharm Beijing Recent Developments
- 4.12 Alembic Pharmaceuticals
- 4.12.1 Alembic Pharmaceuticals Company Information
- 4.12.2 Alembic Pharmaceuticals Business Overview
- 4.12.3 Alembic Pharmaceuticals Olaparib API Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Alembic Pharmaceuticals Olaparib API Product Portfolio
- 4.12.5 Alembic Pharmaceuticals Recent Developments
5 Global Olaparib API Market Scenario by Region
- 5.1 Global Olaparib API Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Olaparib API Sales by Region: 2021-2032
- 5.2.1 Global Olaparib API Sales by Region: 2021-2026
- 5.2.2 Global Olaparib API Sales by Region: 2027-2032
- 5.3 Global Olaparib API Revenue by Region: 2021-2032
- 5.3.1 Global Olaparib API Revenue by Region: 2021-2026
- 5.3.2 Global Olaparib API Revenue by Region: 2027-2032
- 5.4 North America Olaparib API Market Facts & Figures by Country
- 5.4.1 North America Olaparib API Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Olaparib API Sales by Country (2021-2032)
- 5.4.3 North America Olaparib API Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Olaparib API Market Facts & Figures by Country
- 5.5.1 Europe Olaparib API Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Olaparib API Sales by Country (2021-2032)
- 5.5.3 Europe Olaparib API Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Olaparib API Market Facts & Figures by Country
- 5.6.1 Asia Pacific Olaparib API Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Olaparib API Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Olaparib API Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Olaparib API Market Facts & Figures by Country
- 5.7.1 South America Olaparib API Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Olaparib API Sales by Country (2021-2032)
- 5.7.3 South America Olaparib API Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Olaparib API Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Olaparib API Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Olaparib API Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Olaparib API Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Olaparib API Sales by Type (2021-2032)
- 6.1.1 Global Olaparib API Sales by Type (2021-2032) & (Kg)
- 6.1.2 Global Olaparib API Sales Market Share by Type (2021-2032)
- 6.2 Global Olaparib API Revenue by Type (2021-2032)
- 6.2.1 Global Olaparib API Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Olaparib API Revenue Market Share by Type (2021-2032)
- 6.3 Global Olaparib API Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Olaparib API Sales by Application (2021-2032)
- 7.1.1 Global Olaparib API Sales by Application (2021-2032) & (Kg)
- 7.1.2 Global Olaparib API Sales Market Share by Application (2021-2032)
- 7.2 Global Olaparib API Revenue by Application (2021-2032)
- 7.2.1 Global Olaparib API Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Olaparib API Revenue Market Share by Application (2021-2032)
- 7.3 Global Olaparib API Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Olaparib API Value Chain Analysis
- 8.1.1 Olaparib API Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Olaparib API Production Mode & Process
- 8.2 Olaparib API Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Olaparib API Distributors
- 8.2.3 Olaparib API Customers
9 Global Olaparib API Analyzing Market Dynamics
- 9.1 Olaparib API Industry Trends
- 9.2 Olaparib API Industry Drivers
- 9.3 Olaparib API Industry Opportunities and Challenges
- 9.4 Olaparib API Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst